Louise Chen - Cantor Fitzgerald Securities
Okay, thank you.
Operator
Question comes from the line of Ken Cacciatore from Cowen and Company. Please go ahead. Your line is now open.
Ken Cacciatore - Cowen and Company, LLC
Thank you. Flemming, not trying to break any rules of this call, but just wanted to ask one question, then I'll ask an operational question. So first question, how are you able to gauge what Shire shareholders want you to do? I don't know if you can just talk technically about conversations you can have or how do you engage with them, and if you can give any perspective of the feedback you're getting.
And then operationally, if you could just be a little bit more specific on SHP643. Obviously, CINRYZE is doing about 90% of sales in the U.S. With SHP643, it looks like you could be able to finally expand both capacity of CINRYZE into the ex-U.S. markets and maybe SHP643 obviously into those ex-U.S. markets. So is it possible that SHP 643 could equal what you do right now in ex-U.S. markets if you're able to supply? Thank you.
Flemming Ornskov - Shire Plc
Yeah, so, as you can hear, I'm being chaperoned today, and I know that you're never one that's been known to break any rules on questions, Ken, but I can only say to you that, as you know, we have a UK listing. We have two brokers and that's a very good entry (31:38) for myself and also the board to get input of what shareholders think about any particular situation. And, of course, I think both myself and multiple board members and many members of my executive team have lots of exposures to our shareholders, and we make it an absolute priority to do the very best for our shareholders and hear their feedback where we can. But I'm not going to comment specifically on any feedback on this situation.
I think a lot of that feedback has also siphoned into the public domain through analysts' reports or other people that have commented. So I'm not going to comment more on that. But getting the right feedback, hearing that feedback, making sure that's an important part of any decision-making, I can assure you I have a Board of Directors that puts significant emphasis on that, and have an independent channel through our brokers to get that information, I think they get a very good, broad and, I would say, unbiased, unfiltered feedback from our investors.
And also, several members of our board, including our Chairman, has a lot of interactions with investors. So, Susan also has a very good insight into the investors and there's also been engagement in the UK by our board with Investor Forum and others. So, they have a very good idea about what investors, in general, think should be the right thing in this and other situations.
So, you hit a very good point on CINRYZE and that's a good and a sad point. The sad point is, of course, that CINRYZE, I would say, ever since we acquired it,ViroPharma, but I think even before that, were suboptimally supplied outside the U.S. We have, over the last several years up till we shifted the U.S. production to Vienna, our in-house facility that we acquired with the Baxalta acquisition, one of the many benefits from that acquisition, that we now are in a much better situation of supplying the U.S. It takes a bit of time, but we have approval for that site to supply the U.S. So I feel good about the opportunity to supply the U.S.
We're still dependent on Sanquin for ex-U.S. supply and for U.S., we're still dependent on Sanquin for some of the raw materials here. So, we're not totally out of the woods, I would say, in that situation. But as we work this through, we will include more countries, because there's only a few right now where CINRYZE is available. So, that will be an expansion opportunity for CINRYZE.
But I would not, Ken, differentiate between U.S. and non-U.S. physicians. One of the things that I can tell you, my channels of feedback on lanadelumab is equally strong out (34:33) from patients, and particularly physicians, in the U.S. as it is outside the U.S. There's a very high interest in this product. And I think you can also see that through the regulatory situation with accelerated review times. So, I think that there will be significant interest outside of the U.S., of course, if pricing and reimbursement allows this, that this can be broadly available. But we will simultaneously shift also production of CINRYZE into higher gear so that we can supply more markets so there is more choice available for patients around the world.
Any other question?